Evaluation of the roflumilast effect supplemented with linezolid in pleural empyema in rats caused by intrapleural S.aureus inoculation.
In addition to tube drains, pleural empyema is treated with antibiotics and anti-inflammatory drugs. We aimed to evaluate the anti-inflammatory activity of roflumilast combined with linezolid in a rat model of pleural empyema induced by Staphylococcus aureus.A total of 40 rats were separated into 7 groups: Sham (n=4), S. aureus inoculation (n=6), S. aureus + 10 mg/kg linezolid (n=6), S. aureus + 5 mg/kg roflumilast (n=6), S. aureus + 10 mg/kg linezolid+5 mg/kg roflumilast (n=6), S. aureus + 10 mg/kg roflumilast (n=6), and S. aureus + 10 mg/kg linezolid + 10 mg/kg roflumilast (n=6). Linezolid was administered 1 hour before and 12 hours after inoculation with S. aureus. Roflumilast was administered orally as a single dose 30 minutes before inoculation with S. aureus. Compared to linezolid alone, linezolid combined with 5 mg/kg roflumilast provided statistically significant improvement in TNF-alpha, IL-1 beta, vasodilation/congestion, and tissue/pleural PNM infiltration (p<0.05).Linezolid combined with 10 mg/kg roflumilast also provided statistically significant improvement TNF-alpha, IL-1 beta, IL-6, endothelin-1, vasodilation/congestion, mesothelial cell damage, lung tissue PNL, and pleural PNL compared to linezolid alone (p<0.05).Due to its anti-inflammatory effect and significant impact on recovery, roflumilast can be used in conjunction with antibiotherapy for the treatment of pleural empyema.